Meet The Disruptors: Jo Bhakdi Of Quantgene On The Three Things You Need To Shake Up Your Industry
We are on the track of launching Serenity, the world’s first medical solution to protect against multiple cancers through early detection and prevention. This is going to be a big and continuous journey that will ultimately result in cancer being pushed down from places 1–2 for causes of death to place 8 or 9. It’s going to take a while to get there, and it’s worth it.
As a part of our series about business leaders who are shaking things up in their industry, I had the pleasure of interviewing Jo Bhakdi, founder and CEO of Quantgene.
Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine. Prior to Quantgene, Jo founded i2X, an investment framework that composes risk-minimizing Venture Capital portfolios across complex portfolios of technology companies. The i2X platform laid important foundations for advanced analytics in both financial and biotechnology applications, such as the Quantgene machine learning platform. Bhakdi holds a Masters in Economics and Psychology from Tubingen University, one of Germany’s leading academic institutions, with a focus on financial theory and statistics. He kicked off his career at WPP and Omnicom, where he held Strategy and Executive Director positions. Beyond his focus on technology and the future of medicine, Bhakdi is dedicated to bringing together the best and brightest and transforming them into pioneers, pushing the boundaries of health, life, and innovation for all.
Thank you so much for doing this with us! Before we dig in, our readers would like to get to know you a bit more. Can you tell us a bit about your “backstory”? What led you to this particular career path?
It’s great to be here with you, Jason. And thanks for covering the most exciting disruptions that are happening right now. My background is a bit unusual, which…